ASC-J9® increases the bladder cancer chemotherapy efficacy via altering the androgen receptor (AR) and NF-κB survival signals

BACKGROUND: The current chemotherapy regimens may extend survival for patients with metastatic bladder cancer (BCa) for a few months, but eventually most patients succumb to disease because they develop resistance to their chemotherapy. METHODS: TCGA human clinical sample survey and urothelial tumor...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Exp Clin Cancer Res
Main Authors: Huang, Chi-Ping, Chen, Jinbo, Chen, Chi-Cheng, Liu, Guodong, Zhang, Yong, Messing, Edward, Yeh, Shuyuan, Chang, Chawnshang
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6592003/
https://ncbi.nlm.nih.gov/pubmed/31234917
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-019-1258-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados